Emeis

Allowing for the ESG scandal aftermath

19/05/22 -"We reiterate our pessimistic stance on Orpea. On top of those in France, government investigations were recently launched in other European countries (Belgium, Luxembourg, Italy and Switzerland) into ..."

PDF page sample
Pages
54
Language
English
Published on
19/05/22
Download
You may also be interested by these reports :
04/11/26
Fresenius delivered a solid Q3, with revenue broadly in line and adjusted EBIT 3.2% ahead of consensus. Biopharma kept compounding and has already ...
03/11/26
Philips’ Q3 profitability exceeded expectations. Most segments contributed to topline growth, while the largest contributor, Diagnosis treatment, ...
03/11/26
FMC’s Q3 26 beat consensus, but the underlying picture is weak: organic revenue was flat, adjusted EBIT fell 6% and US SMTG worsened to -1.1%. FY26 ...
03/11/26
bioMerieux reported a Q3 sales beat, with top-line growth driven by robust performance across both segments. Despite weak BIOFIRE respiratory panel ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO